MNPR (Monopar Therapeutics) Marketable Securities: $84.95 Mil (As of Mar. 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $106.60
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Marketable Securities?

Monopar Therapeutics MNPR +2.30% 35 Marketable Securities is $84.95 Mil as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Monopar Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $84.95 Mil.

Monopar Therapeutics's annual Marketable Securities increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($14.40 Mil) and increased from Dec. 2024 ($14.40 Mil) to Dec. 2025 ($78.57 Mil).

Monopar Therapeutics  (NAS:MNPR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Monopar Therapeutics Marketable Securities Related Terms

Monopar Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Marketable Securities Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.93 0.00 14.40 78.57

Monopar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.84 13.75 16.00 78.57 84.95
MNPR
35GF Score
Monopar Therapeutics Inc MNPR
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $84.95 Mil mean?
Monopar Therapeutics (MNPR) has a Marketable Securities of $84.95 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Marketable Securities too high?
Monopar Therapeutics' current Marketable Securities is $84.95 Mil. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Marketable Securities compare to MDXG and FTH?
Monopar Therapeutics' Marketable Securities of $84.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Marketable Securities is $84.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Marketable Securities of $84.95 Mil. The current Marketable Securities is $84.95 Mil. Monopar Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Marketable Securities is $84.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$106.60
Price